ACADIA to Host Conference Call and Webcast on Monday, May 11, 2009, at 5:00 p.m. Eastern Time SAN DIEGO—(BUSINESS WIRE)—May. 5, 2009—ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical companyutilizing innovative technology to fuel drug discovery and clinicaldevelopment of novel treatments for central nervous system disorders,today announced that it will report its unaudited financial results forthe first quarter ended March 31, 2009 on Monday, May 11, 2009, afterthe U.S. financial markets close. ACADIA's management will host aconference call and webcast on Monday, May 11, 2009, at 5:00 p.m.Eastern Time to discuss ACADIA’s financial results and developmentprograms.
The conference call may be accessed by dialing 866-825-3209 forparticipants in the U.S. or Canada and 617-213-8061 for internationalcallers (reference passcode 62919191). A telephone replay of theconference call may be accessed through May 25, 2009 by dialing888-286-8010 for callers in the U.S. or Canada and 617-801-6888 forinternational callers (reference passcode 93775458). The conference callalso will be webcast live on ACADIA’s website, www.acadia-pharm.com,under the investors section and will be archived there until May 25,2009.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company utilizing innovative technology tofuel drug discovery and clinical development of novel treatments forcentral nervous system disorders. ACADIA’s most advanced productcandidates include pimavanserin in Phase III for Parkinson’s diseasepsychosis in collaboration with Biovail Laboratories International SRL,a product candidate in Phase II for chronic pain and a product candidatein Phase I for glaucoma, both in collaboration with Allergan, as well asadditional compounds in IND-track development. All of the productcandidates in ACADIA’s pipeline emanate from discoveries made using itsproprietary drug discovery platform. ACADIA maintains a website at www.acadia-pharm.comto which ACADIA regularly posts copies of its press releases as well asadditional information and through which interested parties cansubscribe to receive email alerts.
Source: ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, Director,Investor Relations
Thomas H. Aasen, Vice President and ChiefFinancial Officer
(858) 558-2871